
In order to determine whether high-dose combination chemotherapy was active in chemotherapy resistant patients, 19 patients, (9 with small cell zzso zzso 6 with zzso cell zzso 2 with diffuse zzso lymphoma, 1 with Hodgkin's disease and 1 with zzso 18 of whom had had extensive prior chemotherapy and failed, received 23 courses of high-dose chemotherapy with zzso bone zzso infusion zzso Three patients received four courses of zzso zzso zzso and zzso zzso zzso and 16 patients received 19 courses of zzso and zzso in these doses plus zzso zzso zzso zzso was observed in 6 of 8 zzso small cell zzso zzso patients (1 complete response zzso 4 partial responses zzso 1 less than zzso in 6 zzso cell zzso patients (3 zzso 2 zzso 1 less than zzso in both patients with diffuse zzso zzso (1 zzso 1 less than zzso in the patient with Hodgkin's disease (1 zzso and in the patient with zzso zzso Only 2 patients who had received prior zzso and zzso extensively showed resistance to these zzso The median response duration was 11 weeks zzso zzso zzso + zzso Major toxicity consisted of bacterial zzso Two patients died from treatment related zzso zzso recovered to levels of greater than or equal to zzso zzso zzso by days zzso zzso day zzso and zzso to levels of greater than 100 zzso zzso by days zzso zzso day zzso without any delayed zzso zzso zzso combination chemotherapy with zzso causes acceptable toxicity and high response rates of relatively short duration in tumors zzso to conventional zzso 

